Welcome to our dedicated page for AKSO HEALTH GROUP SEC filings (Ticker: AHG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is dedicated to the SEC filings of Akso Health Group (NASDAQ: AHG), a company that describes its business as spanning social e-commerce in China, medical device sales in China and the United States, radiotherapy oncology services, and online medical consultations. While specific filings are not listed here, investors typically review Akso Health Group’s reports to understand how these activities are reflected in its financial statements, risk disclosures, and corporate structure.
For a company like Akso Health Group, key filings on the SEC’s EDGAR system generally include annual reports on Form 20-F or Form 10-K, which provide a detailed overview of business segments such as healthcare equipment and product trading, medical devices, and oncology or online clinic services. Interim reports can offer updates on changes in operations, equity investments in online clinics, and developments in AI-powered healthcare initiatives like the integration of DeepSeek’s technology.
Investors may also be interested in current reports that describe material events, including notifications from Nasdaq regarding minimum bid price, stockholders’ equity, or filing timeliness, as referenced in the company’s press releases. In addition, insider transaction reports on Form 4, when available, can be used to monitor trading activity by directors and officers.
On Stock Titan, Akso Health Group’s SEC filings page is designed to surface these regulatory documents alongside AI-powered summaries that explain complex sections in plain language. As new filings are posted to EDGAR, they can be reflected here with concise explanations of key points, helping readers quickly identify disclosures related to medical devices, oncology services, online clinics, and AI healthcare initiatives associated with AHG.
Akso Health Group director files initial ownership report
Akso Health Group director Liu Wenjuan has filed an initial statement of beneficial ownership as required for new insiders. The filing shows no reported purchases, sales, gifts, or other transactions, and no derivative positions are listed in this excerpt.
Akso Health Group reports that independent director Gerald T. Neal resigned from the board effective February 28, 2026 for personal reasons, with no disagreement related to the company’s operations or policies. The board appointed Jianqiang Xu as a new independent director effective March 16, 2026, also naming him to the audit, compensation (as chair), and nominating & corporate governance committees.
Xu is a senior neurosurgeon and hospital administrator in China with extensive clinical and academic experience. Under his director offer letter, he will receive $12,000 per year in cash compensation, paid quarterly, plus reimbursement of reasonable expenses, and is subject to confidentiality, non‑competition and non‑solicitation covenants, as well as indemnification provisions.
Akso Health Group director Stephen P. Brown has filed an initial Form 3, formally disclosing his status as a director of the company. The excerpt shows no reported share transactions or derivative positions, indicating this filing is primarily administrative and focused on establishing insider reporting status.
Akso Health Group director Wang Yilin has filed an initial statement of beneficial ownership on Form 3. This filing establishes Wang Yilin’s reporting status as a director of Akso Health Group but does not list any reportable transactions or holdings in this excerpt.
Akso Health Group director Liu Zhe submitted an initial insider ownership report on Form 3. The filing lists Liu as a director but shows no reported transactions, meaning it simply establishes Liu’s status as an insider for future ownership and trading disclosures.
Akso Health Group filed a Form 6-K furnishing unaudited results for the six months ended September 30, 2025. Net revenues were $6.99M, up slightly from $6.93M, and now come entirely from marketing promotion services after medical device sales dropped to zero.
Gross profit rose to $0.62M, lifting gross margin to 8.9% from 2.8%, but general and administrative expenses nearly tripled to $2.06M, leading to a net loss of $1.30M versus a $0.55M loss a year earlier. Basic and diluted loss per share stayed at $0.001.
Cash and cash equivalents fell sharply to $11.1M from $176.2M at March 31, 2025, as the company used $166.4M in investing cash flow, mainly $175.7M of advances for capital expenditures tied to building its Internet Hospital business platform. Total equity was $198.3M against liabilities of $13.7M. Management cites existing cash and committed support from its controlling shareholder as sufficient to fund operations for at least the next twelve months despite an accumulated deficit of $200.2M.
Akso Health Group (AHG) presents a wide-ranging annual report describing a company transitioning from prior microlending activities into an "Internet+healthcare" and social e-commerce model while pursuing medical device sales, online consultations, community health stations and cancer therapy centers. The company reported higher sales and marketing spend of US$168,421 for the year ended March 31, 2024 versus US$6,661 the prior year driven by brand-building for new businesses, and a reduction in general and administrative expenses to US$8.6 million (down 44.7% from US$15.5 million) primarily due to lower provisions for uncollected receivables. The report discloses net income from discontinued operations of US$11.84 million and highlights significant operational and regulatory risk factors, including dependence on suppliers, client concentration, cybersecurity and data-protection obligations, heavy PRC regulatory oversight, potential HFCAA-related listing risks, lack of business insurance, and material uncertainties around approvals, licensing and cross-border capital flows.